Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06379594
Other study ID # 294633
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date June 20, 2022
Est. completion date June 2028

Study information

Verified date April 2024
Source South London and Maudsley NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This project aims to understand the feasibility, acceptability and real-world evidence of a novel UK-based remote brain health clinic for patients with mild cognitive impairment (MCI). A timely and accurate diagnosis of dementia is a priority in the UK and MCI is indicative of future risk of cognitive decline. An accurate etiological diagnosis of MCI (MCI-subtyping - distinguishing those who are likely to go on to develop dementia and those who are not) is vital for treatment planning. Whilst the assessment of molecular biological markers (biomarkers) for etiological diagnosis of MCI and Alzheimer's disease (AD) is increasingly recommended and employed internationally, the uptake is low in UK memory clinics. The Brain Health Clinic (BHC) has been specifically designed as a state-of-the-art diagnostic centre for those with MCI. Procedures will include a range of clinical and biomarker assessments, with molecular biomarkers based on lumbar puncture and cerebrospinal fluid (CSF) analysis. Additionally, the clinic will employ remote neuropsychiatric assessments using digital and telephonic methods. This allows for regular contact, whilst adhering to changes in clinical practice and national guidance due to the COVID-19 pandemic. Our overarching objectives are to first establish the acceptability and feasibility of the remote Brain Health Clinic and its novel clinical and biomarker assessment programme. Then secondly establish the impact of care under the Brain Health Clinic on i) care management decisions (e.g. follow-up and treatment planning); ii) time to etiological diagnosis of MCI (MCI-subtyping); and iii) time to diagnosis of dementia and severity of dementia at the time of diagnosis.


Description:

The Brain Health Clinic is designed to complement the existing memory clinic pathway and will complete the patient journey of patients with mild cognitive impairment (MCI). All patients referred to the new brain health clinic will be assessed using a standardized battery of clinical instruments by qualified clinicians, as per South London and Maudsley (SlaM) memory clinic pathway. In line with clinical practice changes and national guidance due to the COVID-19 pandemic, these assessments will be completed remotely via telephone and/or video conferencing and online. Consenting participants will be invited to complete the Brain health Clinic's initial assessments. All assessments will be completed remotely. Assessments will include cognitive assessments such as Telephone Interview for Cognitive Status Modified version 39 (TICS-M v39), the Clinical Dementia Rating Scale Sum of Boxes (CDR-SoB) for telephone consultations, Computerised Integrated Cognitive Assessment (ICA-comp). The Hospital Anxiety and Depression (HADS) will be used to assess the symptoms of anxiety and depression. For the information from participants' carers/study partners, the following questionnaires will used: Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); Adult Carer Quality of Life Questionnaire (AC-QoL) and Neuropsychiatric Inventory-Questionnaire (NPI-Q). Assessment battery can be completed in more than one session as required. Participants will be given the opportunity to complete self-assessments such as HADS in their own time, prior to the first assessment session. Participants will be reviewed in the clinic at baseline, 6 and 12 months. A biomarker program consisting of lumbar puncture with cerebral spinal fluid (CSF) analysis following international guidelines (Engelborghs et al., 2017) saliva sampling, and electroencephalogram EEG will be applied to every consenting participant. This will be completed within two months of baseline assessment. A safety questionnaire for lumbar puncture will be administered to ensure eligibility for the procedure. The lumbar puncture facilities will be located in the BRC Clinical Research Facility. The CSF samples collected from the lumbar puncture will be shipped to Affinity Biomarker Labs where the analysis will be conducted using a Cobas® 6000 analyser for three assays: Elecsys® β-Amyloid(1-42) CSF, Elecsys® Phospho-Tau (181P) CSF, Elecsys® Total -Tau CSF. Consented samples for future studies will undergo centrifugation, transfer to new tubes, aliquoting into cryovials, and storage at -80 degrees Fahrenheit. Saliva samples will be analysed by Cytox Group Limited, who will employ a polygenic risk scoring algorithm, genoSCORE™-LAB, to identify those at the highest genetic risk of cognitive decline and Alzheimer's disease using genetic data from the saliva sample (Daunt P et al. 2020). EEG will also be offered as an optional investigation to help support the diagnostic process. The EEG will be acquired by a trained researcher or neurophysiologist. The consented participants will also be seen by a phlebotomy trained study researcher who will take blood plasma samples and store them at -80 degrees Fahrenheit. As per clinic guidance, participants with negative CSF biomarker results (indicating that their MCI is unlikely to progress to dementia) will be discharged from the brain health clinic back to their General Practitioners (GP) and so will not complete the 6- and 12-month assessments. They will however complete all appropriate feedback questionnaires and a sub-sample will be invited to participate in a semi-structured interview to further explore their experiences of the remote brain health clinic. The interview will be conducted remotely (by telephone/video conferencing). Questionnaires will be administered to participants concerning the feasibility and acceptability of i) the brain health clinic itself and; ii) the following brain health clinic procedures: lumbar puncture, saliva sampling, EEG ICA-comp assessment and CDR-SoB assessment. Additionally, carers/study partners will be asked to complete a questionnaire concerning their views on the acceptability and feasibility of the brain health clinic. The time from the first assessment until the final diagnosis will be recorded, as well as diagnostic confidence and the plan for future monitoring, outlining the determinants for continued monitoring vs discharge to GP. A subsample of 12 participants will be invited to participate in a semi-structured interview to further explore their experiences of the remote brain health clinic. The interview will be conducted remotely (by telephone/video conferencing). The interviews will be audio recorded with participants' consent and will be transcribed. Thematic analysis will be completed, supported by Nvivo software (Qsr International, 2012). Magnetic resonance imaging (MRI)data obtained as part of the memory service or Brain Health Clinic pathway will be analysed in order to establish the predictive validity of BrainageR software and automated volumetric measures in reference to a normative population. Novel AI and machine learning tools will also be applied to MRI scans alongside existing biomarkers. No MRI scans will be carried out as part of this study. Historical MRI scans will be retrospectively analysed. Historical data on patients receiving MCI and dementia diagnoses will be obtained from the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Clinical Record Interactive Search (CRIS) resource. The CRIS system allows research access to the anonymized electronic health record of one of Europe's specialist dementia care provider and currently data are available for 20,000 patients with dementia and more than 3,000 patients with MCI. The data source has been enhanced through more than 100 natural language processing algorithms, facilitating the extraction of in-depth data from free text, including the degree of cognitive impairment at MCI and dementia diagnosis (Couch et al., 2021). This source will be utilized to identify patients referred to SLAM memory clinics who have been diagnosed with MCI (approximately 10%). The objectives are to determine 1) the time from discharge from the memory clinic with MCI diagnosis to a new referral and dementia diagnosis, and 2) the severity of dementia at the time of diagnosis. A sub-study involving a programme of cognitive training games will be offered to a maximum subset of 30 participants. The games target episodic memory, semantic and spatial abilities, and working memory. Participants will train 5 days per week for 10 weeks. Each training session lasts 24 min, i.e., participants will play 3 games per session each for 8 min. The Quality assurance The monitoring of this trial to ensure compliance with Good Clinical Practice and scientific integrity will be managed by the study team. The research team will have quarterly meetings to monitor the conduct of the trail. A proportion of research projects undertaken within the Institute of Psychiatry, Psychology and Neuroscience, King's College London are selected at random and subjected to internal audit each year. It is anticipated that no further monitoring or auditing will be necessary; however, the Chief Investigator will be available to provide support with any situations that arise which have not been accounted for. Data Management and Monitoring An electronic Case Report Form (CRF) will be used which will be stored in a password protected database which is stored on a password protected encrypted secure network. Access to this document will be restricted to the Chief Investigator and clinical researchers. Study progress and all other aspects of data monitoring will be completed by the Chief Investigator and research team. Quarterly meetings will be held to facilitate this. Statistical analysis: The statistical analysis will mainly consist of descriptive analyses such as mean or median of scale scores with diversity measures (Standard Deviation or Interquartile Range) as appropriate) or proportions with Confidence Interval. Given the cross-sectional nature of the study, significant drop-out is not anticipated; however, a 10% drop-out rate will be factored into the analysis. An interim analysis is scheduled for completion at 12 months. Feedback questionnaires: Acceptability of the brain health clinic and its procedures will be assessed from the perspective of participants via a series of short questionnaires that include both 5-point Likert scales and open-ended questions. The likert scales will contain ordinal variables therefore nonparametric methods will be used to analyse the data collected; the central tendency will be summarised by median or the mode calculations and dispersion summarised by the range across quartiles. The qualitative information obtained by the open-ended questions will be manually coded and analysed by thematic analysis; the software package NVivo will be utilised to support with this. All coding and themes will be checked by a second researcher to ensure that no aspect of the data has been overrepresented. Brain health clinic procedures will be considered acceptable if 70% of participants rate each aspect of acceptability explored as satisfactory or above. Study partners will also complete a questionnaire concerning acceptability, feasibility and clinical value of the brain health clinic. The questionnaire will be analysed utilising the same methods as the participant's questionnaires. Participant semi-structured interviews: Interviews will be audio recorded with participants consent and the results transcribed. An inductive thematic analysis will be completed, supported by Nvivo software (Qsr International, 2012). Braun and Clarke's six phase method for conducting a thematic analysis will be followed (Braun & Clarke, 2006). Themes across the dataset will be checked by a researcher with qualitative experience who is independent of the initial analysis to ensure that no aspect of the data has been under or overrepresented. Themes will be reported to inform any amendments or improvements to the brain health clinic. Lab analysis: CSF - The following Assay system will be used to analyse CSF: ElectroChemiLuminescence Immunoassay Instrument: Cobas® 6000 analyzer series. The Assays are: Elecsys® β-Amyloid(1-42) CSF, Elecsys® Phospho-Tau (181P) CSF & Elecsys® Total -Tau CSF. Saliva - Samples will be analysed by Cytox Group Limited, who will employ a polygenic risk score algorithm, genoSCORE™-LAB, to identify those at highest genetic risk of cognitive decline and Alzheimer's disease using genetic data from the saliva sample. genoSCORE-LAB is a genetic test, that analyses patient genotypes generated from an array of 114,000 single nucleotide polymorphisms - common genetic variations - that are associated with, or protective against, the risk of developing Alzheimer's disease. Blood plasma - Blood samples will be immediately centrifuged. Plasma will be extracted from this sample and stored for future diagnostic dementia research studies (subject to ethical review). Sub-study data analysis: Data will be analysed using frequentist and Bayesian analysis methods. Variables of interest are the maximum level reached and learning slope in each game, reaction times, number of correct answers, and omission/commission errors.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date June 2028
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Suspected Mild Cognitive Impairment requiring further diagnostic work-up to secure etiologic diagnosis, subjective cognitive impairment and mild dementia. - Aged 18 years or over - Fluent in the English language Exclusion Criteria: - A diagnosis of moderate-severe dementia - Unwilling or unable to provide informed written consent to participate

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom King's College London London Denmark Hill

Sponsors (1)

Lead Sponsor Collaborator
South London and Maudsley NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To establish acceptability and feasibility of a novel remote brain health clinic for those with MCI. Number/ proportion of participants accepting each brain health clinic procedures for biomarker testing. From enrollment to the end of the final assessment at 12 months
Primary To establish acceptability and feasibility of a novel remote brain health clinic for those with MCI. Number/proportion of participant and study partner (where available) experience questionnaires on the acceptability and feasibility of remote brain health clinic From enrollment to the end of the final assessment at 12 months
Secondary To establish the acceptability and feasibility of the following procedures/ biomarker assessment in a Brain Health Clinic Number/proportion of participants accepting each of the following brain health clinic procedures for biomarker testing: Lumbar puncture,saliva sampling and EEG From enrollment to the end of the final assessment at 12 months
Secondary 2. To establish the acceptability and feasibility of administering the following cognitive assessments remotely in a brain health clinic Number/proportion of participants completing ICA-comp and CDR-SoB at baseline, 6 months and 12 months. From enrollment to the end of the final assessment at 12 months
Secondary To establish the validity of novel MRI analysis software tools MRI data that have been obtained as part of the memory service or Brain Health Clinic pathway will be analysed in order to establish the predictive validity of BrainageR software and automated volumetric measures in reference to a normative population. Novel AI and machine learning tools will also be applied to MRI scans alongside existing biomarkers Duration of the whole study period from June 20 2022 to June 20 2028
Secondary 5. To investigate the acceptability and feasibility of remote tablet-based cognitive training Number/proportion of participants completing the cognitive training sub-study. Maximum level reached per game. Adherence to training schedule and participant experience of cognitive training. From enrollment to the end of the final session at week 50
Secondary To establish the impact of the remote Brain Health Clinics novel clinical and biomarker assessment programme Time to etiological diagnosis of MCI (MCI-subtyping) utilizing the new brain health clinic set up vs time to etiological diagnosis of MCI in the current pathway. This will be compared with historical data. From enrollment to the end of the final assessment at 12 months
Secondary To establish the impact of the remote Brain Health Clinics novel clinical and biomarker assessment programme Time to diagnosis of dementia and severity of dementia at time of diagnosis using the new brain health clinic setup in comparison with historical controls from the CRIS cohort. From enrollment to the end of the final assessment at 12 months
Secondary To establish the impact of the remote Brain Health Clinics novel clinical and biomarker assessment programme Change in diagnostic confidence before and after CSF analysis data is available and will be measured. From enrollment to the end of the final assessment at 12 months
Secondary To establish the impact of the remote Brain Health Clinics novel clinical and biomarker assessment programme Impact on care management decisions. The role of the results of key brain health clinic assessments (biomarker and clinical) on key management decisions, such as the recommended follow-up procedure (frequency, primary vs secondary care), treatment with cholinesterase inhibitors or memantine, will be recorded. From enrollment to the end of the final assessment at 12 months
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A